Related Experiment Video
Updated: Apr 14, 2026
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Decoding Drug Resistance in Pancreatic Cancer: A Subcellular Structure Perspective
Xiaowen Li1,2, Hao Lyu1,2, Yixin Wu1,2
1National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Hubei University of Technology, Wuhan 430068, China.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with drug resistance representing the primary barrier to effective treatment. Current research has largely focused on individual signaling pathways or isolated organelle functions, yet a comprehensive understanding of how these subcellular structures coordinate to drive resistance remains lacking. This review synthesizes current knowledge through the perspective of subcellular structural homeostasis, the dynamic balance maintained by intracellular organelles. We examine how key subcellular structures, the cell membrane, mitochondria, endoplasmic reticulum, ribosomes, lysosomes, exosomes, and stress granules, undergo functional remodeling to promote drug resistance. It is crucial that these organelles do not work independently but form an integrated and dynamic communication network. Mitochondria serve as the intracellular signaling hub, integrating calcium signals, metabolic progress, and stress responses, while exosomes function as intercellular messengers that spread the anti-drug-resistant phenotype between cells. This framework reveals why targeting individual structures often fails and highlights the therapeutic potential of disrupting inter-organelle communication. We discuss emerging clinical strategies targeting subcellular structures and identify critical knowledge gaps, including the need for non-invasive biomarkers and combination approaches that target multiple network nodes. By shifting the focus from isolated organelles to their coordinated interplay, this review offers a new paradigm for overcoming drug resistance in PDAC.
Insights
Pancreatic ductal adenocarcinoma (PDAC) drug resistance stems from coordinated organelle communication, not isolated pathways. Targeting this network offers new therapeutic strategies for this lethal cancer.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer where drug resistance is a major treatment obstacle.
- Current research often examines single pathways or organelles, neglecting their coordinated roles in resistance.
- A comprehensive understanding of how subcellular structures interact to drive PDAC drug resistance is lacking.
Purpose of the Study:
- To review and synthesize current knowledge on subcellular structural homeostasis in the context of PDAC drug resistance.
- To examine the functional remodeling of key organelles (cell membrane, mitochondria, ER, ribosomes, lysosomes, exosomes, stress granules) in promoting resistance.
- To propose a new paradigm focusing on inter-organelle communication networks for therapeutic strategies.
Main Methods:
- Literature review synthesizing current research on organelle function and communication in PDAC.
- Analysis of how individual subcellular structures contribute to drug resistance.
- Examination of the integrated network of organelle communication, including mitochondria as signaling hubs and exosomes as intercellular messengers.
Main Results:
- Subcellular structures like mitochondria and exosomes play critical roles in a coordinated network that promotes PDAC drug resistance.
- Mitochondria act as central signaling hubs, integrating metabolic and stress signals.
- Exosomes facilitate intercellular communication, spreading drug resistance phenotypes.
Conclusions:
- Targeting individual organelles is often ineffective due to their interconnectedness.
- Disrupting inter-organelle communication networks holds significant therapeutic potential for PDAC.
- Future strategies should focus on combination approaches and non-invasive biomarkers to target these networks effectively.
